ALK’s EURneffy secures MHRA approval for anaphylaxis treatment

ALK has received marketing authorisation from the MHRA for EURneffy 1mg, a needle-free adrenaline treatment for children with anaphylaxis. The authorisation extends access to a treatment option previously confined to injection-based administration. Anaphylaxis is a rapidly progressing and potentially life-threatening allergic reaction that requires immediate treatment. Credit: Evgeniia Primavera / Shutterstock.com. ALK has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for EURneffy 1mg, a needle-free adrenaline treatment for children with anaphylaxis. This approval is said to be the first in the UK for a needle-free adrenaline treatment for children aged four years and older,…

Source: Pharmaceutical Technology